Newswise — Princeton, NJ—December 1, 2015—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced today a new Student Network benefit that now provides ISPOR student members with complimentary access to FormularyDecisions.com®.
FormularyDecisions.com® is a centralized, web-based payer ecosystem developed by Dymaxium Inc. that connects current and future health care decision makers with evidence from leading scientific sources, insights from health technology assessment (HTA) and other authoritative reviews, and tools to efficiently evaluate and compare life science products for evidence-based decisions.
Current ISPOR student members can access this new benefit online at http://www.ispor.org/student/FormularyDecisions.asp by logging in with their ISPOR student member information. Future ISPOR student members can find out more and apply for membership at http://www.ispor.org/members/MembershipIndex.aspx. ISPOR student members must be full-time graduates or undergraduate students or academic fellows and must show proof of current enrollment.
###
ABOUT ISPORThe International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that promotes health economics and outcomes research excellence to improve decision making for health globally. Web: www.ISPOR.org | LinkedIn: http://bit.ly/ISPOR-IN | Twitter: http://bit.ly/ISPOR-T (@ISPORorg) | YouTube: http://bit.ly/ISPOR-YT |Facebook: http://bit.ly/ISPOR-FB
ABOUT DYMAXIUM INCDymaxium is a trusted market access partner differentiated by a singular focus; creating stronger connections between Payers and life sciences companies via technology. With expertise from more than 1000 unique payer-focused tools and solutions and access to over 1200 registered payers as part of the formularydecisions.com® ecosystem, Dymaxium leverages these unique assets to generate data and drive insights for improved reimbursement decisions.Web: www.dymaxium.com | LinkedIn: https://www.linkedin.com/company/dymaxium-inc- | Twitter: @dymaxium
RSS